The important contribution of lipid levels to CVD risk notwithstanding, only a limited number of the 95 loci were associated with coronary artery disease. 11 A possible explanation is the typically small effect sizes of these common genetic variants individually. To obtain further insight into the genetic architecture underlying CVD, and to obtain more insight into the possibility of detecting individuals at increased risk for CVD based on their genetic profile, we investigated the same genetic risk scores used in the GLGC publication 11 to test the hypothesis that the cumulative effects of such common genetic lipid variants are associated with subclinical atherosclerosis and incident coronary heart disease (CHD).
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results
Descriptive statistics for the 2 populations are provided in Table 1 . Except for sex and systolic blood pressure, all tested characteristics exhibited significant differences between the populations, which differ by 2 decades in age. Among the 8130 Rotterdam Study (RS) participants, 499 myocardial infarction (MI) cases (mean follow-up 9.76 years) and 1194 CHD cases (mean follow-up 9.54 years) were present. Exclusion of prevalent cases resulted in 398 MI and 924 CHD cases. Table 2 provides means of the risk scores, and the mean number of risk alleles, for the various sets of lipid SNPs as well as the total number of SNPs used to compute the scores. The means and SDs of the TC, LDL-C, HDL-C, and TG risk scores were similar in Erasmus Rucphen Family (ERF) and the RS, as were the means, SDs, and overall distributions of risk alleles (Figure) . Numbers of overlapping SNPs and loci between each pair of risk scores are depicted in Table 3 . Detailed information about the exact SNPs used to compute the 4 risk scores is depicted in Table I in the online-only Data Supplement, which was adapted from Table II in the onlineonly Data Supplement from the GLGC article. 11 All 4 risk scores were robustly associated with their corresponding lipid levels in both cohorts separately, as well as in the meta-analysis ( Table II in the online-only Data Supplement). Effect estimates were similar in both cohorts. The proportion of variance of the lipid levels explained by the genetic risk scores ranged from 6% for TG to 8% for TC for 1 SD increase in score above the mean.
The associations between the genetic risk scores and carotid atherosclerosis measures are described in Table 4 . The TC risk score (Table 4 ) was nominally associated with carotid intima-media thickness (IMT) in both the age and sex-adjusted and full models in ERF (P=0.021 and P=0.044). This risk score was not associated with IMT in the RS. In the meta-analysis of the 2 populations, there was only a borderline association in the full model (P=0.071). In terms of carotid plaque score, the TC score was robustly associated in both cohorts individually and in meta-analysis. The metaanalysis results demonstrated an increase in plaque score of 0.094 per SD increase in risk score in the age and sex-adjusted model (P=3.97×10 −7 ) and 0.106 per SD increase in the fully adjusted model (P=4.91×10 −8 ). The effect size estimates were consistent between each of the 2 populations. The LDL-C risk score (Table 4 ) was marginally associated with IMT in both the age and sex-adjusted model (β=0.006; P=0.051) and the full model (β=0.005; P=0.039). The magnitude of the association was slightly higher than for the TC risk score. With respect to plaques, the LDL-C score was strongly associated. Each SD increase in risk score resulted in an ≈0.1 increase in plaque score (P=3.15×10 −8 in the age and sex model; and P=3.18×10 −8 in the full model). The regression coefficients for the association with plaque score were very similar to those in the TC risk score models. As was the case for the TC risk score, the associations between the LDL risk score and plaque would survive any correction for multiple-testing. The genetic HDL-C risk score was not associated with IMT (Table 4 ), but it was modestly associated with plaque. An SD increase in the genetic score increased plaque by ≈0.04 (P≈0.02), irrespective of the model. However, as with the associations between the TC and LDL-C scores and IMT, this association would not survive a reasonable multiple-testing correction. Similarly, the TG risk score ( Table 4 ) was modestly associated with plaque in the full model (β=0.052; P=0.008). The effect estimate was slightly lower, and the P value substantially higher, in the model that only adjusted for age and sex (β=0.037; P=0.048).
In the models that showed significant association between the genetic risk scores and IMT or plaque, the lipid levels corresponding to the genetic risk scores were included in the model. After inclusion of these lipid levels, effect estimates for the genetic risk scores were lower and P values higher, but there were still significant associations: the TC and LDL-C scores were still associated with plaque in the full model (TC: β=0.054; P=0.010; LDL-C: β=0.047; P=0.040) and marginally associated in the age and sex-adjusted model (TC: β=0.038; P=0.053; LDL-C: β=0.042; P=0.060).
The analyses of the relationships between the genetic risk scores and incident MI and CHD are presented in Table 5 . For all of the models tested, proportionality assumptions were met (minimum P=0.18). The TC and LDL-C scores ( Table 5) were associated with both MI and CHD. The effect estimates were consistent across models and, after the exclusion of prevalent cases, were similar for MI and CHD (hazard ratios [HRs] ≈1.10). The P values increased in the full models, and with prevalent cases excluded, as would be expected because of reductions in sample size. The findings for CHD were particularly strong; all models achieved at least nominal significance for both the TC and LDL-C risk scores (P between 0.045 and 7.0×10 −4 ). There were no significant associations between the HDL-C and TG risk scores (Table 5 ) with either incident MI or CHD, irrespective of the inclusion or exclusion of prevalent cases, although there was a borderline association between the TG score and CHD (HR [95% confidence interval]=1.05 [1.00-1.11]; P=0.071).
Inclusion of TC levels in the models that assessed the association of the TC genetic risk score with MI and CHD resulted in lower HRs and higher P values, but associations with CHD were still borderline significant in the age and sex-adjusted models (HR [95% confidence interval] all: 1.06 [1.00-1.13], prevalent excluded: 1.07 [0.99-1.14]). Adding LDL-C to the models that showed significant association of the LDL-C genetic risk score with MI or CHD resulted in HRs similar to those in the original models. P values were higher, but still (borderline) significant for the associations with CHD (P=0.004-0.068). For the MI outcome, only a borderline significant association remained in the age and sex-adjusted model without exclusion of the prevalent cases (P=0.071).
The associations between the pure genetic risk scores for LDL-C, HDL-C, and TG with atherosclerosis, after exclusion of the variants that were also associated with at least 1 of the other lipid measures, are described in Table III in the onlineonly Data Supplement. Although P values were higher and effect estimates slightly lower, the LDL-C risk score was still associated with plaque score. Additionally, the LDL-C score was borderline associated with IMT, whereas the pure HDL-C and TG risk scores still showed marginal association with plaques. Table IV in the online-only Data Supplement describes the associations of the 3 pure genetic risk scores (for LDL-C, HDL-C, and TG) with MI and CHD in the RS. Effect estimates for the associations of the LDL-C score with MI and CHD were similar to those for the original risk score and remained significantly associated with both outcomes in the age and sex-adjusted model. In the full model, the score was still at least borderline significantly associated with both outcomes when prevalent cases were not excluded. After exclusion of prevalent cases, only a borderline significant association with CHD was left. Table V in the online-only Data Supplement describes area under the curves (AUCs) for the prediction of incident MI and CHD in the RS. Framingham Risk Score (FRS) discriminated MI better than the genetic risk scores combined (AUC 0.65 versus AUC 0.62) and combining both slightly and only borderline significantly improved the results compared with the FRS AUC alone (AUC 0.66; P=0.069). For the CHD outcome, results were similar: the AUC for the FRS was 0.65, 0.61 for the genetic risk scores combined, and 0.65 for the FRS and genetic risk scores combined with a slightly narrower confidence interval than for the FRS alone. However, this improvement was not significant. Figure I in the onlineonly Data Supplement shows the receiver-operating characteristic curves for the prediction of MI and CHD. In bold, the numbers of SNPs used to compute the genetic risk scores; above the diagonal, the numbers of SNPs shared by the pairs of risk scores; below the diagonal, the numbers of loci shared by the pairs of risk scores. HDL-C indicates high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SNP, single nucleotide polymorphism; TC, total cholesterol; and TG, triglycerides.
Discussion
This study shows that aggregations of common genetic variants influencing lipid levels play a significant role in the development of atherosclerosis and the subsequent occurrence of CVD despite generally small effects on lipid levels individually. All genetic risk scores (for TC, LDL-C, HDL-C, and TG) were associated with carotid plaque with the effects of the TC and LDL-C scores being ≈2.5× as large as the effects of the HDL-C and TG scores. IMT was marginally associated with the LDL-C score. The TC and LDL-C scores were robustly associated with incident CVD, especially with a composite CHD phenotype.
Associations of the TC and LDL-C risk scores with plaque were still at least marginally significant after inclusion of the lipid levels corresponding to the genetic risk score in the models. The TC and LDL-C scores were also still (borderline) significantly associated with MI and CHD. These findings suggest some added value of these genetic risk scores beyond the lipid levels themselves. This may be because they reflect lifelong exposure to higher lipid values (in contrast to fluctuating occasional lipid measurements), which would make genes relevant for early prediction and prevention purposes. A recent Framingham Heart Study article described a significant association of an LDL-C genetic risk score with coronary artery calcium that vanished after inclusion of LDL-C levels in the model. 13 This study, however, found a stronger association of early and long-term average lipid levels compared with current measures. This supports the idea that risk scores reflecting long-term elevated lipid levels may be of use compared with current lipid measurements.
After exclusion of the variants from the genetic risk scores for LDL-C, HDL-C, and TG that were also associated with at least 1 of the other outcomes, most P values were higher and, for the atherosclerosis outcomes, effect estimates slightly lower. However, these risk scores were still associated with plaque, and the LDL-C score was still associated with MI and CHD in most models, showing that these associations did not result solely from the influence of variants associated with one of the other lipid outcomes.
Although the HDL-C and TG risk scores were associated with plaque, the evidence for association with subclinical atherosclerosis and incident CVD obtained for these scores was clearly weaker compared with the TC and LDL-C scores. This is in line with evidence from 2 recent studies. 14, 15 In one study, we analyzed 1987 genotyped RS participants who underwent computed tomography of the aortic arch and carotid arteries to quantify atherosclerotic calcification. 14 In that study, we demonstrated that genetic risk scores comprised of TC and LDL-C SNPs were more predominantly associated with larger calcification volumes than HDL-C and TG risk scores in all vessel beds. In the other study, association between risk scores based on previously reported lipid SNPs and CHD was assessed in 2 UK cohorts of middle-aged men and women. Similar to our findings, the TC and LDL-C risk scores were associated with higher CHD risk in both cohorts (odds ratios, 1.30-1.42 for individuals in the highest quintiles of the risk scores compared with individuals in the lowest quintiles). In these cohorts, the HDL-C score was not associated with the outcome, and the TG score was only associated in 1 of the 2.
Our findings are also in line with the evidence for causal association of HDL-C and TG levels themselves with CVD, which has not been as solid as the evidence for TC and LDL-C levels. 4, 16 In a recent large Mendelian randomization study, a single polymorphism in the endothelial lipase gene and a risk score based on 14 SNPs that are exclusively associated with HDL-C were investigated for association with HDL-C levels and with MI. 17 In this study, both the single SNP and the risk score were associated with HDL-C levels, but not with MI. These findings suggest that at least some genetic mechanisms Full model adjusted for age, sex, current and former smoking, hypertension, body mass index, diabetes mellitus, and alcohol consumption. CHD indicates coronary heart disease; CI, confidence interval; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol; Meta, meta-analysis; MI, myocardial infarction; TC, total cholesterol; and TG, triglycerides.
that raise HDL-C do not lower risk of MI. TG has been considered a biomarker for CVD because of its association with other atherogenic particles rather than being directly atherogenic. 16 However, this was challenged by the identification of a genetic variant consistently associated with TG that was also associated with incident CHD. 18 It is remarkable that all genetic risk scores were associated with carotid plaque and only the LDL-C score with IMT. An explanation might be that the plaque score, in contrast to IMT, is based on a direct measurement of the presence of atherosclerotic plaques and, thus, better represents atherosclerosis. In the RS, carotid plaques were more strongly associated with coronary calcification than with common carotid IMT. 19 An association between IMT and coronary calcification was present in that study, suggesting that carotid IMT may be regarded as a measure of generalized atherosclerosis. The finding that this association was weaker, however, supports the idea that carotid plaques better represent the presence of atherosclerosis.
In a previous study, we observed that genetic risk scores for lipids, based on 26 loci, did not improve prediction of incident CHD. 10 Although the number of lipid loci increased to 95, the FRS still discriminated MI and CHD better than the genetic risk scores in our study and combining both only marginally improved the FRS AUC. However, because the genetic risk scores are invariant over time, they may prove useful for risk stratification at younger ages, where the clinical models may not be as effective. Moreover, despite the large number of lipid loci that have been discovered, there is still substantial missing heritability. The 95 GLGC loci, plus an additional 26 identified by conditional association analyses, explained 9.6% to 12.4% of the total variance in the 4 lipid traits in the Framingham Heart Study. This corresponds to ≈25% to 30% of the estimated heritability. 11 As we further elucidate the genetic basis for lipid levels, the predictive ability of genetic risk scores should improve.
Different hypotheses have been developed about the genetic architecture underlying common complex traits and diseases. The common disease, common variant hypothesis argues that common variants with modest effects underlie many complex traits. 20, 21 However, for most complex phenotypes, the currently known common variants only explain a small portion of the estimated trait heritability. This is also the case for the common genetic CHD variants identified by a large GWAS meta-analysis comprising 22 233 cases and 64 762 controls. Those variants, in addition to the lead SNPs of previously established loci, explain ≈10% of the heritability of CHD. 22 The common disease, rare variant hypothesis, by contrast, posits that less frequent variants with larger effect sizes underlie genetic susceptibility to many common complex diseases. 20, 21 One cause of CVD, for example, is familial hypercholesterolemia, in which rare LDL receptor mutations exert a large influence on lipid levels and subsequent premature CVD. 23, 24 Our results show that the combined effects of numerous common variants associated with small effects on lipid levels are associated with the risk of subclinical (plaque) and, in the case of the genetic risk scores for TC and LDL-C, clinical outcomes, including CHD.
In a recent study, common and rare variants identified by the 1000 Genomes Project and by resequencing 7 genes in loci associated with LDL-C doubled the estimated heritability of LDL-C accounted for by these genes, indicating that both additional common and rare variants influence blood lipid levels. 25 With ongoing efforts in gene discovery, such as 1000 Genomes-based imputations and whole exome and genome sequencing, it is likely that many more variants, spanning a broad frequency range, will be discovered. The identification of these might improve the ability to detect individuals at increased risk for CVD. Finally, it may be that the cumulative effects of genetic variants associated with other intermediate phenotypes, such as blood pressure and obesity, will also be associated with CVD. Genetic risk scores based on these endophenotypes, in combination with those derived from the lipids, might lead to improved detection of individuals at increased risk for CVD.
Major strengths of our study are the use of populationbased cohorts for the assessment of the risk scores and the weighting of the SNPs by the effect estimates obtained in the discovery cohorts. This gives an indication of the performance of risk scores, based on common variants and their effect estimates resulting from large GWAS, in the general population. Because both ERF and the RS were part of the discovery GWAS meta-analysis, a limitation of this study might be that results are slightly overestimated. However, because of the very large number of individuals that were included in the GLGC meta-analysis and that were not part of the ERF or RS cohorts, this effect is expected to be limited. The small number of individuals in this study compared with the discovery GWAS might even have led to false-negative results.
In conclusion, our results show that the cumulative effects of common genetic variants associated with TC, LDL-C, HDL-C, and TG are associated with subclinical outcomes, such as carotid plaque. The genetic risk scores for TC and LDL-C are also associated with incident CHD. Although genetic risk scores did not improve clinical AUCs, our study provides evidence for the added value of genetic risk scores above lipid levels themselves when studying subclinical atherosclerosis and CHD. As our knowledge of genetic variation increases, preclinical genetic screening tools might detect individuals at increased risk for CVD and, thus, enhance prediction and prevention of clinical events. Initiative). The generation and management of genome-wide association studies genotype data for the Rotterdam Study is supported by the NWO Investments (nr. 175.010.2005.011, 911-03-012). This study is funded by the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), The Netherlands Genomics Initiative/ NWO project nr. 050-060-810, Consortium on Health and Aging Network of Cohorts in Europe and the United States (nr 242244).
